| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1904-07-12 |
| Identifiers | MRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976 |
| Document date | 1971-07-13 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review on apalutamide and leuprolide. [S]
Mr. Neruda returns four weeks after starting apalutamide and three weeks after his first leuprolide injection, with a professional Spanish interpreter. The right hip pain has eased to 2 of 10 and no longer wakes him; he takes acetaminophen once a day at most. He gets up to pass urine twice a night instead of three times. Mild hot flashes began last week. His energy is a little lower in the afternoons. He has had no rash, falls, dizziness, leg weakness or numbness. He saw his dentist a week ago; no dental work is needed. He takes vitamin D every day. The germline test result came back last week: no harmful variant was found. He had his radiotherapy planning visit, and treatment starts in two weeks. Before radiotherapy, his bowels are regular, once a day, with no bleeding. [S]
| Element | Detail |
|---|---|
| Treatment | Apalutamide four weeks; leuprolide three weeks ago |
| Symptoms | Pain 2 of 10; nocturia twice; mild hot flashes; no rash or falls |
| Results since last visit | Germline panel negative; dental examination clear |
| Next step | Radiotherapy to the prostate starts in two weeks |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower afternoon energy; weight stable |
| Endocrine | Positive | Mild hot flashes for a week |
| Musculoskeletal | Positive | Right hip pain 2 of 10 |
| Integumentary | Negative | No rash or itch |
| Gastrointestinal | Negative | Bowels regular once a day; no bleeding |
| Neurological | Negative | No weakness, numbness or dizziness |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1966-04-06 to 1971-07-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1971-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 1971-06-01 to 1971-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 1971-06-15 | active | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks | One injection every twelve weeks | Intramuscular route | 1971-06-22 | active | S |
| Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 1971-06-15 | active | S |
| Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation | One injection every six months | Subcutaneous route | 1971-07-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1971-07-13 | Body height | 178 | cm | S |
| 1971-07-13 | Body weight | 92.8 | kg | S |
| 1971-07-13 | Body mass index (BMI) [Ratio] | 29.3 | kg/m2 | S |
| 1971-07-13 | Systolic blood pressure | 152 | mm[Hg] | S |
| 1971-07-13 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 1971-07-13 | Heart rate | 76 | /min | S |
| 1971-07-13 | Respiratory rate | 14 | /min | S |
| 1971-07-13 | Body temperature | 36.6 | Cel | S |
| 1971-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1971-07-13 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.2 | ng/mL | <=4 ng/mL | High | S |
| 1971-07-13 | Testosterone [Mass/volume] in Serum or Plasma | 22 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 1971-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-07-13 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1971-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1971-07-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1971-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 7-55 U/L | Normal | S |
| 1971-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 1971-07-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 40-129 U/L | High | S |
| 1971-07-13 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1971-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 28 | ng/mL | 30-100 ng/mL | Low | S |
| 1971-07-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1971-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1971-07-13 | International Prostate Symptom Score [IPSS] | 14 | {score} | S | ||
| 1971-07-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S |
Vital signs recorded on 1971-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; walks without favoring the right hip |
| Cardiovascular | Regular rhythm; blood pressure 152/90 mm Hg on repeat; no ankle swelling |
| Skin | No rash |
| Neurological | Strength and sensation normal in both legs |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months; an early value here for symptomatic disease | Completed today | 6.2 ng/mL, down from 46.8 |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 22 ng/dL, castrate |
| Laboratory | Chemistry with calcium and alkaline phosphatase | Before denosumab; periodically in metastatic disease | Completed today | Calcium 9.3 mg/dL; creatinine 0.98 mg/dL; ALT 25 U/L; alkaline phosphatase 141 U/L, falling |
| Laboratory | 25-hydroxyvitamin D | Before a bone-protective drug and periodically | Completed today | 28 ng/mL, up from 22 |
| Laboratory | TSH on apalutamide | Periodically, about every four months | Completed today | 2.4 mIU/L, the first value, four weeks into treatment |
| Laboratory | Baseline TSH before apalutamide missed | Before starting apalutamide | Deferred | Ordered at the last visit but not drawn, a deviation from the protocol: the order was not on the laboratory requisition sent with the germline sample. Today's value is normal, so a pre-existing thyroid problem is unlikely and no harm has resulted, but a true baseline is lost. Corrective action: the apalutamide start checklist now includes TSH, drawn with the first prescription |
| Laboratory | Hemoglobin A1c and lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline six weeks ago; A1c again at three months |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline four weeks ago |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 152/90 mm Hg, above goal; amlodipine raised |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 2 of 10, down from 6 |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit | Completed today | IPSS 14, down from 17 |
| Survey | Bowel function before radiotherapy | Baseline before radiotherapy | Completed today | Regular once a day; no bleeding |
| Medication safety | Rash on apalutamide | Every visit on androgen deprivation | Completed today | None |
| Medication safety | Falls on apalutamide | Every visit on androgen deprivation | Completed today | No falls or dizziness |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Mild; no treatment wanted |
| Medication safety | Denosumab: calcium, vitamin D and dental check before the first dose | Before each dose | Completed today | Calcium normal; vitamin D rising; dental examination clear a week ago; first dose given today |
| Referral | Germline testing result | Once | Completed today | No pathogenic variant on a multigene panel including BRCA1, BRCA2, ATM, CHEK2, PALB2, HOXB13 and the mismatch repair genes |
| Referral | Somatic tumor testing | Once, for metastatic disease | Ordered | Sent on the biopsy tissue; pending |
| Referral | Radiotherapy to the prostate | Once | Ordered | Planning done; 20 fractions start in two weeks |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit |
| Self-management | Physical activity and calcium intake | Every visit | Completed today | Walking most afternoons; light resistance exercise started; calcium from food |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)
Follow-up: Radiotherapy from two weeks' time. Home blood pressure readings through the portal in two weeks. Review in nine weeks, at three months, with PSA, testosterone, blood count, chemistry, TSH and hemoglobin A1c, and the second leuprolide injection. Next scheduled visit 1971-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. [S]